Prosight Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History
Bought
Maintained
Sold
Other funds holding LKFT
Prosight Management's LKFT Position: Q3 2026 in Review
Prosight Management reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 2.2% in Q3 2026, selling an estimated $1.29M and leaving 1,998,400 shares worth $59.3M. The position accounts for 11.49% of the portfolio, ranked #1.
Prosight Management first reported a position in LKFT in Q4 2018 and has held it in 24 quarters since. The position peaked at $61.3M in Q2 2026. 95 funds tracked by Wall St. Rank hold LKFT as of Q3 2026.
- Prosight Management held 1,998,400 shares of Lakefront Biotherapeutics American Depositary Shares worth $59.3M as of Q3 2026.
- Prosight Management sold 44,944 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2026, an estimated $1.29M.
- Lakefront Biotherapeutics American Depositary Shares made up 11.49% of Prosight Management's portfolio in Q3 2026, its #1 holding.
- Prosight Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2018 and has held it in 24 quarters since.
- Prosight Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $61.3M in Q2 2026.
- 95 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2026.
Based on Prosight Management's 13F filing for Q3 2026, filed 13 Nov 2026.